Health
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Manchestertimes
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved…
-
Business22 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News22 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Noosa News23 hours agoYoung voices shape Sunshine Coast’s future
-
Noosa News20 hours agoSudden death investigation, Maroochydore – Sunshine Coast